PSCA: prostate stem cell anitgen and uses thereof
AssigneeThe Regents of the University of California
InventorsRobert E. Reiter, Owen N. Witte, Douglas C. Saffran
Life of this patent
Estimating the term…
Abstract
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Claims68
A monoclonal antibody which specifically binds to the extracellular domain of the PSCA antigen.
A monoclonal antibody selected from the group consisting of (a) monoclonal antibodies 1G8, 2A2, 2H9, 3C5, 3E6, 3G3 or 4A10, produced by the hybridomas designated HB-12612, HB-12613, HB-12614, HB-12616, HB-12618, HB-12615, and HB-12617, respectively, as deposited with the American Type Culture Collection;
- (b) a monoclonal antibody which competitively inhibits the binding of any of the monoclonal antibodies of (a);
- and (c) a monoclonal antibody which has the antigen binding region residues of any of the monoclonal antibodies of (a).
A method of inhibiting the growth of tumor cells expressing PSCA, comprising administering to a patient an antibody which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the tumor cells.
A method of inhibiting the growth of tumor cells expressing PSCA, comprising administering to a patient a combination of monoclonal antibodies which bind specifically to PSCA antigen in an amount effective to inhibit growth of the tumor cells.
A method of treating a patient susceptible to or having a cancer which expresses PSCA antigen, comprising administering to said patient an effective amount of an antibody which binds specifically to the extracellular domain of PSCA.
Dependencies are inferred from the claim text.